The Effect Of Carboxymethyl (Cm) Glucan As An Adjunct To Inhaled Corticosteroid Plus Long Acting Beta 2 Agonist In Children With Moderate Persistent Asthma: A Randomized Controlled Trial

Jemaila  B. Valles,; Vicente Carlomagno  D. Venturina Ii,; Yadnee  V. Estrera,; Maritess  A. Arquiza,; Cesar  M. Ong,

The Effect Of Carboxymethyl (Cm) Glucan As An Adjunct To Inhaled Corticosteroid Plus Long Acting Beta 2 Agonist In Children With Moderate Persistent Asthma: A Randomized Controlled Trial

Vicente Carlomagno D. Venturina Ii | Yadnee V. Estrera | Maritess A. Arquiza | Jemaila B. Valles | Cesar M. Ong

Abstract:

INTRODUCTION: Asthma is a chronic disorder of the airways which involve several inflammatory cells and mediators that result to airway hyperresponsiveness. This inflammatory reaction can be prevented by preventing allergic sensitization by way of immunotherapy. This study determined the effect of CM glucan in the prevention of asthma among children. METHODS: A randomized, double blind, placebo controlled trial was carried out in 40 patients ages 6 to 12 years old with moderate persistent, partly and uncontrolled asthma. They were assigned to either placebo or glucan group. Daytime and nighttime coughing, exacerbations, limitation of activities, use of relievers, FEV1 and level of control were assessed. RESULTS: The results of this trial showed that in the CM glucan group more subjects showed improvement in terms of daytime and nighttime cough; need for relievers; exacerbations; and level of control. However, the difference in proportion is minimal and is not statistically significant. CONCLUSION: CM Glucan did not significantly improve symptoms of asthma particularly daytime and nighttime cough, need for relievers; exacerbations, FEV1 and level of control after 31/2 months of treatment in children with moderate persistent asthma.

References:

Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA) Guidelines, 2008.
Chernick, V., and Boat, T. Disorders of the Respiratory Tract in Children. 7th ed. Elsevier Inc., 2006, pp. 808–810.
Liu, A.H., and Leung, D.Y. Renaissance of the Hygiene Hypothesis. J Allergy Clin Immunol. 2006;117:1063–1066.
Shirakawa, T., Enomoto, T., Shimazu, S., and Hopkin, J.M. The Inverse Association Between Tuberculin Responses and Atopic Disorder. Science. 1997;275:77–79.
Erb, K.J., Holloway, J.W., Sobeck, A., Moll, H., and Le Gros, G. Infection of Mice with Mycobacterium bovis-Bacillus Calmette-Guerin (BCG) Suppresses Allergen-induced Airway Eosinophilia. J Exp Med. 1998;187:561–569.
Hansen, G., Yeung, V.P., Berry, G., Umetsu, D.T., and DeKruyff, R.H. Vaccination with Heat-killed Listerias Adjuvant Reverses Established Allergen-induced Airway Hyperreactivity and Inflammation: Role of CD8+ T Cells and IL-18. J Immunol. 2000;164:223–230.
Lehne, G., Hanebergerg, B., Gaustad, P., Johansen, P., Preus, H., and Abraham, T. Oral Administration of a New Soluble Branched β-1,3-D-glucan is Well Tolerated and Can Lead to Increased Salivary Concentrations of Immunoglobulin A in Healthy Volunteers. Clinical and Experimental Immunology. 2005;143:68–69.
Chan, G., Chan, W., and Yuen Sze, D. The Effects of β-glucan on Human Immune and Cancer Cells. Journal of Hematology and Oncology. 2009;2:25.
Kirmaz, C., Bayrak, P., Yilmaz, O., and Yukse, H. Effects of Glucan Treatment on the Th1/Th2 Balance in Patients with Allergic Rhinitis: A Double-blind Placebo-controlled Study. Eur Cytokine Netw. 2005;16(2):128–134.
Yamada, J., Hamuro, J., Hatanaka, H., Hamabata, K., and Kinoshita, S. Alleviation of Seasonal Allergic Symptoms with Superfine β-1,3-glucan: A Randomized Study. J Allergy Clin Immunol. 2007;119(5):1119–1126.
Por, E., Sarinho, E., Medeiros, P., Schor, D., Rego, S., Sales, V., Motta, M.E., Costa, A., Azoubel, A., and Rizzo, J.A. Production of Interleukin-10 in Asthmatic Children After Beta 1-3 Glucan. Allergologia et Immunopathologia. 2009;37(4):188–192.
Generally Recognized As Safe (GRAS) Notice for Yeast Beta Glucan. Federal Register. 1997;62 FR 18938.
Tseng, S.H., Fu, L.S., Nong, B.R., Weng, J.D., and Shyur, S.D. Changes in Serum Specific IgG4 and IgG4/IgE Ratio in Mite Sensitized Taiwanese Children with Allergic Rhinitis Receiving Short-term Sublingual-Swallow Immunotherapy: A Multicenter, Randomized, Placebo-controlled Trial. Asian Pacific Journal of Allergy and Immunology. 2008;26:105–112.
Bahceciler, N.N., Arikan, C., Taylor, A., et al. Impact of Sublingual Immunotherapy on Specific Antibody Levels in Asthmatic Children Allergic to House Dust Mites. Int Arch Allergy Immunol. 2005;136:287–294.
Tari, M.G., Mancino, M., and Monti, G. Efficacy of Sublingual Immunotherapy in Patients with Rhinitis and Asthma Due to House Dust Mite: A Double-blind Study. Allergol Immunopathol. 1990;18:277–284.